A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
about
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsUnraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cellsFurther insight into AE37 peptide vaccination in prostate cancer.
P2860
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A pilot study in prostate canc ...... omarkers for clinical benefit.
@en
type
label
A pilot study in prostate canc ...... omarkers for clinical benefit.
@en
prefLabel
A pilot study in prostate canc ...... omarkers for clinical benefit.
@en
P2093
P2860
P1476
A pilot study in prostate canc ...... omarkers for clinical benefit.
@en
P2093
Anastasios Thanos
Constantin N Baxevanis
Eleftheria A Anastasopoulou
Hubert Kalbacher
Ioannis F Voutsas
Michael Papamichail
Sonia A Perez
Theodora Keramitsoglou
P2860
P2888
P304
P356
10.1007/S00262-015-1717-1
P577
2015-05-31T00:00:00Z
P6179
1041251655